Evidence map›Paper›PMID 27733628›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2016

Modafinil Activates Phasic Dopamine Signaling in Dorsal and Ventral Striata.

Martin J Bobak, Matthew W Weber, Melissa A Doellman, Douglas R Schuweiler, Jeana M Athens, Steven A Juliano, Paul A Garris

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Modafinil, an atypical CNS stimulant?Advances in pharmacology (San Diego, Calif.) · 2024
    Article
  4. Negative allosteric modulation of CBPharmacological research · 2022
    Article
  5. Review
  6. Review
  7. Article
  8. The Novel Atypical Dopamine Uptake InhibitorFrontiers in pharmacology · 2019
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Martin J BobakSchool of Biological Sciences, Illinois State University, Normal, Illinois.
Matthew W WeberSchool of Biological Sciences, Illinois State University, Normal, Illinois.
Melissa A DoellmanSchool of Biological Sciences, Illinois State University, Normal, Illinois.
Douglas R SchuweilerSchool of Biological Sciences, Illinois State University, Normal, Illinois.
Jeana M AthensSchool of Biological Sciences, Illinois State University, Normal, Illinois.
Steven A JulianoSchool of Biological Sciences, Illinois State University, Normal, Illinois.
Paul A GarrisSchool of Biological Sciences, Illinois State University, Normal, Illinois pagarri@ilstu.edu.
Illinois State University · US

Funding

A Closed-Loop Microsystem for Neuromodulation of Reward CircuitryR21DA036331 · NIDA · CASE WESTERN RESERVE UNIVERSITY · PI GARRIS, PAUL A, MOHSENI, PEDRAM · 2013 to 2014
$389k
NIDA NIH HHS R21 DA036331
6 · The paper itself

Abstract

Modafinil (MOD) exhibits therapeutic efficacy for treating sleep and psychiatric disorders; however, its mechanism is not completely understood. Compared with other psychostimulants inhibiting dopamine (DA) uptake, MOD weakly interacts with the dopamine transporter (DAT) and modestly elevates striatal dialysate DA, suggesting additional targets besides DAT. However, the ability of MOD to induce wakefulness is abolished with DAT knockout, conversely suggesting that DAT is necessary for MOD action. Another psychostimulant target, but one not established for MOD, is activation of phasic DA signaling. This communication mode during which burst firing of DA neurons generates rapid changes in extracellular DA, the so-called DA transients, is critically implicated in reward learning. Here, we investigate MOD effects on phasic DA signaling in the striatum of urethane-anesthetized rats with fast-scan cyclic voltammetry. We found that MOD (30-300 mg/kg i.p.) robustly increases the amplitude of electrically evoked phasic-like DA signals in a time- and dose-dependent fashion, with greater effects in dorsal versus ventral striata. MOD-induced enhancement of these electrically evoked amplitudes was mediated preferentially by increased DA release compared with decreased DA uptake. Principal component regression of nonelectrically evoked recordings revealed negligible changes in basal DA with high-dose MOD (300 mg/kg i.p.). Finally, in the presence of the D2 DA antagonist, raclopride, low-dose MOD (30 mg/kg i.p.) robustly elicited DA transients in dorsal and ventral striata. Taken together, these results suggest that activation of phasic DA signaling is an important mechanism underlying the clinical efficacy of MOD.

Indexed as

AnimalsBenzhydryl CompoundsBiological TransportDopamineElectric StimulationMaleModafinilNeostriatumRatsRats, Sprague-DawleySignal TransductionBenzhydryl CompoundsDopamineModafinil

Identifiers

PMID27733628
PMCPMC5118647
OpenAlexW2530702585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.